|
시장보고서
상품코드
2008107
상의세포종 치료제 시장 : 약제 종류별, 질환 종류별, 유통 채널별, 지역별Ependymoma Drug Market, By Drug Type, By Disease Type, By Distribution Channel, By Geography |
||||||
상의세포종 치료제 시장은 2026년에 1억 7,230만 달러로 추정되며, 2033년까지 2억 3,940만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 4.8%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 1억 7,230만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 4.80% | 예측 금액(2033년) | 2억 3,940만 달러 |
상의세포종은 뇌종양 중 드물게 발생하는 뇌종양으로, 뇌교종이라고 불립니다. 뇌 또는 척수의 상피세포에서 발생합니다. 상의세포종은 소아 및 성인에게 발생할 수 있습니다. 부드럽고, 회색빛을 띠거나 붉은 색을 띠는 종양으로 낭종이나 석회화를 포함할 수 있습니다. 상의세포종의 증상은 종양이 뇌에 있는지 척수에 있는지에 따라 달라집니다. 이러한 종양은 상의하종, 점액유두상 상의세포종, 미분화 상의세포종, 고전적 상의세포종 등 4가지 주요 유형으로 나뉩니다. 상의세포종의 증상은 종양의 부위나 크기와 관련이 있습니다. 유아의 경우, 머리 둘레가 커지는 것이 초기 증상 중 하나가 될 수 있습니다. 종양이 성장함에 따라 불쾌감, 불면증, 구토가 나타날 수 있습니다. 나이가 많은 어린이와 성인의 경우 메스꺼움, 구토, 두통이 가장 흔한 증상입니다.
시장 역학
세계 상의세포종 치료제 시장에서 활동하는 주요 기업들은 상의세포종에 대한 연구 개발 강화에 주력하고 있으며, 이는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2022년 4월 소아뇌종양 컨소시엄은 재발성 수모세포종 및 상의세포종 소아 환자를 대상으로 뇌실내 옴브르타맙을 이용한 방사면역요법 2상 임상시험을 개시했습니다. 이 시험은 2030년 7월 30일에 완료될 예정입니다. 또한, 상의세포종에 대한 연구 자금의 증가는 예측 기간 동안 세계 상의세포종 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2021년 11월, 예일대 공중보건대학원의 연구진이 이끄는 과학자 팀은 주로 젊은 성인에게 영향을 미치는 저악성 뇌종양인 저악성 뇌종양의 분자 진화를 조사하기 위해 1,300만 달러의 보조금을 받았습니다.
본 보고서의 주요 특징
- 세계의 상의세포종 치료제 시장을 상세히 분석하고, 2021년을 기준 연도로 하여 예측 기간(2022-2030년)의 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 세계 상의세포종 치료제 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 작성되었습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- "세계 상의세포종 치료제 시장" 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 상의세포종 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 상의세포종 치료제 시장 : 약제 종류별(2026-2033년)
제5장 세계의 상의세포종 치료제 시장 : 질환 종류별(2026-2033년)
제6장 세계의 상의세포종 치료제 시장 : 유통 채널별(2026-2033년)
제7장 세계의 상의세포종 치료제 시장 : 지역별(2026-2033년)
제8장 경쟁 구도
제9장 섹션
KSMEpendymoma Drug Market is estimated to be valued at USD 172.3 Mn in 2026 and is expected to reach USD 239.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 172.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.80% | 2033 Value Projection: | USD 239.4 Mn |
Ependymoma is a rare type of brain tumour called a glioma. It starts from ependymal cells in the brain or spinal cord. Ependymomas can develop in children and adults. They are soft, grayish, or red tumors which may contain cysts or mineral calcifications. Symptoms of ependymomas depend on whether the tumor is in the brain or the spinal cord. These tumors are divided into four major types, subependymoma, myxopapillary ependymoma, anaplastic ependymoma and classic ependymomas. Symptoms of an ependymoma are related to the location and size of the tumor. In infants, increased head size may be one of the first symptoms. Irritability, sleeplessness, and vomiting may develop as the tumor grows. In older children and adults, nausea, vomiting, and headache are the most common symptoms
Market Dynamics
Key players operating in the global ependymoma drug market are focusing on increasing research and development for ependymoma which is expected to drive the market growth during the forecast period. For instance, in April 2022, Pediatric Brain Tumor Consortium initiated Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma. The study is estimated to be completed in July 30, 2030. Moreover, increasing research funding for ependymoma is expected to propel growth of the global ependymoma drug market over the forecast period. For instance, in November 2021, a team of scientists led by researchers at the Yale School of Public Health had received a US $13 million grant to investigate the molecular evolution of lower grade gliomas, slow growing but malignant brain tumors that primarily affect young adults.
Key features of the study
- This report provides an in-depth analysis of the global ependymoma drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ependymoma drug market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Fera Pharmaceuticals, Pfizer, Novartis AG, Merck KGaA, Baxter, Cipla Limited, Zydus Cadila, Lupin Pharmaceuticals, Inc., UCB, Inc., APOTEX INC, and Moleculin Biotech, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ependymoma drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ependymoma drug market
Market Segmentation
- Global Ependymoma Drug Market, By Drug Type
- Corticosteroids
- Antiseizure Agents
- Others
- Global Ependymoma Drug Market, By Disease Type
- Subependymoma
- Myxopapillary Ependymoma
- Anaplastic Ependymoma
- Classic Ependymomas
- Global Ependymoma Drug Market, By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Ependymoma Drug Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Fera Pharmaceuticals
- Pfizer
- Novartis AG
- Merck KGaA
- Baxter
- Cipla Limited
- Zydus Cadila
- Lupin Pharmaceuticals, Inc.
- UCB, Inc.
- APOTEX INC
- Moleculin Biotech, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channels
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Collaboration and Acquisition
- Porters Analysis
- Pipeline Analysis
4. Global Ependymoma Drug Market, By Drug Type, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2030 (%)
- Y-o-Y Growth Analysis, 2022 - 2030
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
- Antiseizure Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
5. Global Ependymoma Drug Market, By Disease Type, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2030 (%)
- Y-o-Y Growth Analysis, 2022 - 2030
- Segment Trends
- Subependymoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
- Myxopapillary Ependymoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
- Anaplastic Ependymoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
- Classic Ependymomas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
6. Global Ependymoma Drug Market, By Distribution Channel, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2030 (%)
- Y-o-Y Growth Analysis, 2022 - 2030
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
7. Global Ependymoma Drug Market, By Region, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033 (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033 (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033 (USD Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033 (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033 (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026-2033 (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Fera Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck KGaA,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Baxter
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- UCB, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- APOTEX INC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Moleculin Biotech, Inc.,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Fera Pharmaceuticals
9. Section
- Research Methodology
- About us
